CLINICAL_TRIALS
trial_result
· 2013-05-22
Clinical Trial Update: Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients [Phase 3]
Summary
Phase 3 study update reporting long-term safety and tolerability of a one-month degarelix dosing regimen in Korean men with prostate cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2013-05-22